It seems it is business as usual for Mind Medicine, aka MindMed, (NASDAQ: MNMD) as the firm gave updates on The post MindMed Expects Results For...
Cybin, a biopharmaceutical company focused on progressing Psychedelics to Therapeutics outlined its upcoming priorities and near-term milestones that...
The early results of a COMPASS Pathways clinical trial quell some concerns related to the safety of psychedelic therapy for individuals with bipolar disorder. The...
Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced the distribution...
The article Atai Announces Disappointing Results in PCN-101 Phase 2a Trial was originally published on Microdose. The industry has been waiting for these...
Atai plans to continue working with its compound despite the setback. The post Atai Life Sciences Ketamine Treatment for Depression Fails in Mid-Stage...
Business analysts take to their crystal balls to provide an industry outlook. The post An Objective Look at the Psychedelics Industry for 2023 appeared...
Administering psychedelics via IV potentially offers better control. The post Tryp Therapeutics Sets Stage for IV-Channeled Psilocybin Trials appeared...
PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of...
Universal Ibogaine (TSX.V: IBO), a life sciences company with a mission to transform the addiction treatment industry with medicalized ibogaine-centered...